**Second Malignancy In A Patient With Long Survival From Solitary Plasmacytoma Previously Treated With Radiation: A Case Study**

\* A. A. Adenipekun \*\*M.A Jimoh, \*T.N Elumelu

\*Department of Radiotherapy College of Medicine, University of Ibadan, \*\*Dept. of Radiotherapy

University College Hospital, Ibadan.

**Abstract:** Plasma cell neoplasms represent a spectrum of diseases characterized by clonal proliferation and accumulation of immunoglobulin thereby producing terminally differentiated B cells. Solitary plasmacytoma is the localized diseases that can arise from the bone while extramedullary plasmacytoma arise in the soft tissue. This research details the case study of a 39 year old man with worsening recurrent epistaxis. It is suggested from this study that radiotherapy could potentially cause second malignancy in survival patients from solitary plasmacytoma.

**[**A. A. Adenipekun, M.A Jimoh, T.N Elumelu. **Second Malinancy In A Patient With Long Survival From Solitary Plasmacytoma Previously Treated With Radiation.** *Cancer Biology* 2015;5(4):22-244]. (ISSN:2150-1041). <http://www.cancerbio.net>. 4. doi:[10.7537/marscbj050415.04](http://www.dx.doi.org/10.7537/marscbj050415.04).

**Background**

Plasma cell neoplasms represent a spectrum of diseases characterized by clonal proliferation and accumulation of immunoglobulin (Ig) – producing terminally differentiated B cells (1). Plasmacytoma comprise < 10% of plasma cell dyscrasia(2).

There are two types of plasmacytoma: solitary and Extramedullary plasmacytoma. Solitary plasmacytoma is the localized diseases that can arise from the bone while extramedullary plasmacytoma arise in the soft tissue (3).

Solitary or multiple extramedullary plasmacytomas have been described in the liver, spleen, lymph nodes, kidneys, subcutaneous tissue and brain parenchyma.

The incidence rate rises with advancing age, with a median age at diagnosis of 70 years and < 1 % of cases are diagnosed in persons < 35 years, for plasma cell myeloma while the median age at diagnosis of solitary plasmacytoma is 55 to 65 years, on average about 10 years younger than patients with multiple myeloma 4,5 males are affected predominantly (male: female ratio 2:1 (6).Solitary plasmacytoma requires specialized techniques for accurate staging, including a CT scan and MRI to exclude more disseminated disease(1).

A monoclonal protein in the serum is observed in 24% to 54% of patients, but in the remaining cases no detectable monoclonal protein is seen, even on immunofixation.Extramedullary plasmacytomas are diagnosed less frequently and require a work up, including MRI and positron emission-tomography to rule out additional sites or disseminated disease.

In solitary plasmacytoma, the diagnosis is established when a solitary lytic lesion is shown by needle or surgical biopsy to be composed of plasma cells and marrow aspiration from a distant site contains less than 5 percent plasma cell 7. Extramedullary plasmacytoma on biopsy is composed of plasma cells.

**Case Reporting**

A 39 year old man who was referred to Radiotherapy clinic, University College Hospital, Ibadan with 5 years history of recurrent epistaxis, progressively worsening. He presented with nasal bleeding of 5 years duration and progressive swelling of the face of 2 years duration (in Nov. 25, 1997) with associated nasal obstruction, weight loss and anorexia. Examination revealed a young man, not pale, bilateral purulent conjunctival hyperemia. Direct examination revealed swelling on the frontal sinus, soft fluctuant, non-pitting extending over the hair margin, fullness and obliterating of the nasal bridge involving the median canthus. Swelling over the antrum, soft, non-pitting, non-tender with trismus.

**Nose**

Pale, fleshy mass obliterating both nasal cavities within the vestibule.

**Oral Cavity**

Trismus, Good oral hygiene, no loosening or loss of teeth

Cranial Nerves

1 – anomic

6- palsy

Other systems were within normal limit.

Hematological, Biochemical and Radiological work up including FBC, E&U,CR, LFT, clotting profile, Retroviral Screening, CT Brain all showed Normal except CT Brain that showed malignant and vascular tumor of the frontal bone involving the nasal bones and para nasal sinuses, and compressing the frontal brain tissue. The frontal bone was completely destroyed and frontal brain tissue was covered by only the skin.He had biopsy and histology came out to be Solitary plasmacytoma.He received 3 weekly combination chemotherapy with vincristine, Adriamycin and cyclophosphamide x 6 courses and Radiotherapy total of 60Gy to Right and Left lateral face and 10Gy to the Anteriorface between 28-11-97 to 12- 1-1998.And 30Gy to the Right Anterior face between 15 – 11 – 99 to 2 – 12 – 1999 with remarkable tumor regression and improvement in apatients’ daily activities, pain was controlled with analgesics. Patient was seen on follow-up for 3 years (1999- 2002) during which the lesion was observed to have regressed with no neural deficit, because of the vulnerability of the frontal brain to injury he was advised to put on helmet when outside the house. Patient was however lost to follow-up for 10 years and showed up this years with no recurrence on the primary site. New frontal bone was noticed to have been formed and patient general health was stable with no central nervous system symptoms.

Patient however complained of painful ulcer on the right lower mandible and biopsy was taken and report come as squamous cell carcinoma. This was completely different from the first histology of plasmacytoma for which he received external Radiotherapy however the site of present disease was in the field of previous treatment. This is therefore suggestive of a second malignancy appearing 13 years after the initial external Radiotherapy. He has since been commenced on chemotherapy vizcisplatin and 5 fluorouracil in preparation for further Radiotherapy.

Hematological, Biochemical and Radiological work up including FBC, RVS, E&U,CR, Skull, Jaw and Chest X – Ray showed normal.

Pain controlled on analgesic.

**Discussion**

Plasmacytoma comprise < 10% of plasma cell dyscrasia. Less commonly solitary plasmacytoma presents in an extramedullary site (20%) usually as a mass in the upper aero respiratory passages that produces local compressive symptoms 5,6,8.It increases with advancing age. Generally they are all highly radiosensitive (3) many cases are reported in literature of high rate 5 years survival. Radiation therapy is the standard treatment for solitary plasmacytoma. Surgery is consider for bone instability fractures, or when there is rapidly progressive neurologic deterioration such as spinal cord compression10,11.

This patient presented with a large tumor with good disease control which is not similar to Ozsahin *et al.*11 that reported that local control was better with small tumors{<4cm} in patients treated with radiotherapy. Solitary plasmacytomaare radiation –sensitive tumors. The patient received high grade radiotherapy which is similar to Ozsahin *et al.* that reported that higher dose can be given to improve local control.

This patients presented with 5 years history of recurrent epistaxis, and 2 years history of progressive facial swelling with associated nasal obstruction. Because of the geographical location of the tumor, surgery could not be done. The benefit of chemotherapy, either alone or in combination with radiotherapy and surgery, as primary therapy has not been proven(2). Moreover, the benefit of adjuvant chemotherapy given to prevent recurrent disease and or progression to myeloma is also undefined.

A recent report suggest that the disappearance of protein after involved field radiotherapy predicts for long-term diseases free survival and possible cure(9). Long-term follow-up is require for all patients treated for solitary plasmacytoma of bone and extramedullary plasmacytoma. More than 50% of cases with solitary plasmacytoma of bone progress to multiple myeloma at 5 years (KNOBEL et al 2006), and approximately 15% of patients with extramedullary plasmacytoma progress to multiple myeloma at 10 years after treatment (Aleqxiou et al 2000).In UCH cancer registry over a period of ten years, we saw a total of 12 cases of Plasmacytoma (10 male, 2 female). Radiation exposure is a well-established risk factor for developing second malignance neoplasm, estimating the true incidence of radiation-induced second malignance neoplasm is difficult. This is due to the fact that, in addition to radiation exposure, the genetic abnormalities (e.g., Li-Fraumeni syndrome) and risk factors associated with primary tumors (e.g., smoking) could predispose the individuals to develop a second cancer.13,14Radiation induced second malignance neoplasm has also been observed at high doses of radiation of up-to 45Gy15, although this patent received up to 60 Gy which was high dose. The development of second malignance neoplasm in patients treated with radiotherapy has been reported to follow a similar timeline of 10-60 years for solid tumoil.16,17,18119,20 This patient had second malignance in the oral cavity thirteen years after initial treatment. Multiple epidemiological studies have confirmed the importance of age in predicting second malignance neoplasm risk at the time radiation exposure. For the same dose, patients exposed to radiation during childhood are at a significantly higher risk for developing second malignance neoplasm compared to those exposed at older age21,22. This patient was thirty nine years old when he received initials radiotherapy. Radiotherapy and chemotherapy are associated with an increased risk of second malignant neoplasm after cancer treatment according to Guerins *et al.* Patients receive both chemo and radiotherapy together.

**Conclusion**

The local control can be achieved in this disease with chemo-radiation, it was not however clear if the second malignancy was due to the radiotherapy but there was a suspicion because the previous radiotherapy field was inclusive of the site.

**Corresponding Author:**

A.A Adenipekun MBBS, FMCR, FWACS,

Department of Radiotherapy, College of Medicine, University of Ibadan,

Ibadan, Oyo State, Nigeria.

Email- adenipek2000@yahoo.com

**References:**

1. Vincent T. Devita (Editor), Samuel Hellman, Steven A. Rosenberg (Editor) By Lippincott: Principles and Practice of Oncology 6th edition (July 2001**):** by Williams & Wilkins Publishers, Page 1816, Section 46.4.

2. James F. Holland, MD, ScD (hc), Emil Frei, III, MD, Donald W. Kufe, MD, and Robert C. Bast, Jr, MD: Holland-Frei Cancer Medicine. 6th edition**:** Principles of Medical OncologyChapter42(page 1347).

3. Jiade J. LV and Luther W. BradyRadiation Oncology page 429 – 441 chapter 29.

4. Ries LAG, Eisner MP, Kosary CL, et al, Eds. SEER cancer statistics review, 1975 to 2002. Bethesda, MD: National cancer Institute, 2005.

5. OZ Sahin M, T Sang RW, poortmans, P, et al outcomes and patterns of failure in solitary plasmacytoma. A multi center Race cancer Network study of 258 patients Int. J. Radiat. Oncol. Biol. Phys. 2006, 64: 210 to 217.

6. Strojan P, Soba E, Lamovel S, et al Extramedullary plasmacytoma: clinical and histopathologic study. Int. J. Radiat. Oncol. Biol. Phys 2002: 53: 692 to 701.

7. Text book of Hematology by William H. Williams Ernest Beutler Allan J. Erslev. Marshall A. Lichtman. Forth Edition.

8. Alexioul L, Kau R J, Dietztfelbinger H, et al. Extramedullary plasmacytomatumouroccurence and therapeutic concepts. Cancer 1999 86: 4305 – 2314

9. Dimopoulos M A, Goldstein J, Fuller L, Deiasalle K, Alexanian R, Curability of solitary bone plasmacytoma J. Clin. Oncol. 1992: 10: 587- 590.

10. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, DjulbegovicB,Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hemas

11. Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, OnerDincbas F, Landmann C, Castelain B, Buijsen J, Curschmann J, Kadish SP, Kowalczyk A, Anacak Y, Hammer J, Nguyen TD, Studer G, Cooper R, Sengöz M, Scandolaro L, Zouhair A. Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients. Int J Ra

12. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.

13. Li F.P., Fraumeni J.F. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?Ann. Intern. Med. 1969;71:747–752.

14. Sasco A.J., Secretan M.B., Straif K. Tobacco smoking and cancer: A brief review of recent epidemiological evidence. Lung Cancer. 2004;Suppl. 45:S3–S9.

15. Sachs R.K., Brenner D.J. Solid tumor risks after high doses of ionizing radiation. Proc. Nat. Acad. Sci. USA. 2005;102:13040–13045. doi: 10.1073/pnas.0506648102.

16. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. National Research Council of the National Academies; Washington, DC, USA: 2006.

17.  Hall E.J., Giaccia A. Radiobiology for the Radiologist. Lippincott Williams and Wilkins; Philadelphia, PA, USA: 2011.

18.  Meadows A., Friedman D., Neglia J., Mertens A., Donaldson S., Stovall M., Hammond S., Yasui Y., Inskip P. Second neoplasms in survivors of childhood cancer: Findings from the childhood cancer survivor study cohort. J. Clin. Oncol. 2009;27:2356–2362.

19.  Chaturvedi A.K., Engels E.A., Gilbert E.S., Chen B.E., Storm H., Lynch C.F., Hall P., Langmark F., Pukkala E., Kaijser M., et al. Second cancers among 104,760 survivors of cervical cancer: Evaluation of long-term risk. J. Nat. Cancer Inst. 2007;99:1634–1643. doi: 10.1093/jnci/djm201.

20.  Reulen R., Frobisher C., Winter D., Kelly J., Lancashire E., Stiller C., Pritchard-Jones K., Jenkinson H., Hawkins M. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer.JAMA. 2011;305:2311–2319.

21. Hall E.J. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 2006;65:1–7. doi: 10.1016/j.ijrobp.2006.01.027.

22. International Commission on Radiological Protection. Recommendations. Annals of the ICRP Publication 60; Ottawa, Canada: 1990.

11/22/2015